| Leukemia, Myelocytic, Acute

Trisenox vs Rezlidhia

Side-by-side clinical, coverage, and cost comparison for leukemia, myelocytic, acute.

Deep comparison between: Trisenox vs Rezlidhia with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsRezlidhia has a higher rate of injection site reactions vs Trisenox based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Rezlidhia but not Trisenox, including UnitedHealthcare

Category

Trisenox

Rezlidhia

At A Glance

RouteIntravenous

FrequencyDaily

ClassArsenical antineoplastic

RouteOral

FrequencyTwice daily

ClassIDH1 inhibitor

Indications

Leukemia, Myelocytic, Acute

Leukemia, Myelocytic, Acute

Dosing

Acute Promyelocytic Leukemia (newly-diagnosed low-risk) Induction: 0.15 mg/kg/day IV daily in combination with tretinoin until bone marrow remission, not to exceed 60 days. Consolidation: 0.15 mg/kg/day IV daily for 5 days per week during weeks 1-4 of each 8-week cycle for 4 cycles in combination with tretinoin.

Acute Promyelocytic Leukemia (relapsed or refractory) Induction: 0.15 mg/kg/day IV daily until bone marrow remission, not to exceed 60 days. Consolidation: 0.15 mg/kg/day IV daily for 25 doses over a period of up to 5 weeks, beginning 3 to 6 weeks after completion of induction.

Leukemia, Myelocytic, Acute 150 mg orally twice daily until disease progression or unacceptable toxicity; take on an empty stomach at least 1 hour before or 2 hours after a meal.

Contraindications

Hypersensitivity to arsenic

—

Drug Interactions

1352View drug interactions

297View drug interactions

Adverse Reactions

Most common (>=30%) Nausea, cough, fatigue, pyrexia, headache, abdominal pain, vomiting, tachycardia, diarrhea, dyspnea, hypokalemia, leukocytosis, hyperglycemia, hypomagnesemia, insomnia, dermatitis, edema, QTc prolongation, rigors, sore throat, arthralgia, paresthesia, pruritus

Serious Differentiation syndrome, cardiac conduction abnormalities, QTc prolongation, encephalopathy, hepatotoxicity, hyperleukocytosis, atrial dysrhythmias, hyperglycemia

Postmarketing Ventricular tachycardia, torsade de pointes, atrioventricular block, congestive heart failure, deafness, pancytopenia, bone marrow necrosis, peripheral neuropathy, seizures, confusion, encephalopathy, Wernicke's encephalopathy, posterior reversible encephalopathy syndrome, toxic epidermal necrolysis, rhabdomyolysis, melanoma, pancreatic cancer, squamous cell carcinoma

Most common (>=20%) AST increased, ALT increased, potassium decreased, sodium decreased, alkaline phosphatase increased, nausea, creatinine increased, fatigue/malaise, arthralgia, constipation, lymphocytes increased, bilirubin increased, leukocytosis, uric acid increased, dyspnea, pyrexia, rash, lipase increased, mucositis, diarrhea, transaminitis

Serious Differentiation syndrome, transaminitis

Pharmacology

The mechanism of action is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in promyelocytic leukemia cells and causes damage or degradation of the PML-RAR-alpha fusion protein.

Olutasidenib is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1); it inhibits mutant IDH1 proteins (R132H, R132C, and others), reducing 2-hydroxyglutarate (2-HG) levels in leukemia cells and promoting differentiation.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Trisenox